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Corticosteroids (aldosterone, cortisol/corticosterone) exert direct functional effects on cardiomyocytes. However, gene networks activated by
corticosteroids in cardiomyocytes, as well as the involvement of the mineralocorticoid receptor (MR) vs the glucocorticoid receptor (GR) in these
effects, remain largely unknown. Here we characterized the corticosteroid-dependent transcriptome in primary culture of neonatal mouse
cardiomyocytes treated with 10−6 M aldosterone, a concentration predicted to occupy both MR and GR. Serial analysis of gene expression
revealed 101 aldosterone-regulated genes. The MR/GR specificity was characterized for one regulated transcript, namely ecto-ADP-
ribosyltransferase-3 (Art3). Using cardiomyocytes from GR(null/null) or MR(null/null) mice we demonstrate that in GR(null/null) cardiomyocytes
the response is abrogated, but it is fully maintained in MR(null/null) cardiomyocytes. We conclude that Art3 expression is regulated exclusively
via the GR. Our study identifies a new set of corticosteroid-regulated genes in cardiomyocytes and demonstrates a new approach to studying the
selectivity of MR- vs GR-dependent effects.
© 2006 Elsevier Inc. All rights reserved.Keywords: Cardiomyocytes; Aldosterone; Glucocorticoids; Mineralocorticoid receptor; Glucocorticoid receptorThe effects of adrenal corticosteroids (aldosterone, cortisol,
or corticosterone in rodents) on the cardiovascular system have
recently attracted considerable attention because of their
possible involvement in the pathophysiology of heart disease.
The RALES and EPHESUS clinical trials have shown that
mineralocorticoid receptor (MR) antagonists added to a
standard drug regimen substantially increase survival and
decrease hospitalization in patients with heart failure [1,2].
Systemic glucocorticoids have also been recently recognized as
a risk factor for heart failure [3]. In transgenic mouse studies,⁎ Corresponding authors. Fax: +41 21 6925355.
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resulted in severe heart failure and cardiac fibrosis [4]. In the
opposite experiment, when MR was overexpressed in cardio-
myocytes, severe ventricular arrhythmia was observed as a main
phenotype [5]. Together, these findings provide experimental
evidence that the MR signaling pathway could be involved in
heart disease. However, on the molecular level, the effects of
corticosteroids on cardiomyocytes remain poorly understood.
In vitro, corticosteroids have been shown to exert direct
functional effects on cardiomyocytes. Whitehurst et al. showed
that dexamethasone, a synthetic glucocorticoid, significantly
increased the L-type Ca2+ currents in neonatal rat cardiomyo-
cytes [6]. Schulz et al. have shown that dexamethasone inhibits
inducible nitric oxide synthase activity in adult rat
Table 1
SAGE tags differentially expressed between Aldo and control SAGE libraries
SAGE tag Ctrl Aldo p Accession No. Gene
Induced tags
TACAAAAAAA 14 28 * NM_001013028.1 Expressed sequence AI597468
CAGGAAAGCA 11 26 * NM_019657.2 Hydroxysteroid (17-β-dehydrogenase 12)
CCGGGCAATG 10 25 * M_011817.1 Gadd45g
CCAGCCCTGG 10 20 * NM_008963.1 Prostaglandin D2 synthase (brain) (Ptgds)
TTTGGAAAAA 9 26 ** NM_027695.1 RIKEN cDNA
CAGGACCTGG 9 19 * NM_028677.3 RIKEN cDNA
CAGATGGTGA 8 20 * NM_009814.1 Calsequestrin 2 (Casq2)
TATACAGTCG 7 19 * XM_485637.2 Ribosomal protein L7 (Rpl7)
GGATTCAATA 6 19 ** NM_181728.1 ADP-ribosyltransferase 3 (Art3)
TTCAATAAAT 6 19 ** XM_123229.4 Mortality factor 4-like 1 (Morf4l1)
CAGCTCCTAA 5 18 * NM_028733.1 PKC and casein kinase substrate (Pacsin3)
TCTAAAAAAA 5 17 * NM_145963.1 Potassium channel (Kcnj14)
CCTAAAAAAA 5 16 * NM_011246.2 RAS guanyl-releasing protein 1 (Rasgrp1)
CTGGCAGTGG 3 15 ** NM_007379.1 ATP-binding cassette Abca2
TTCAATAAAT 3 11 * XM_123229.4 Mortality factor 4-like 1 (Morf4l1)
AAATAAAGTT 3 10 * XM_484784.2 Sperm equatorial segment protein 1 (Spesp1)
CTTTCTCAGT 3 10 * NM_007669.2 Cyclin-dependent kinase inhibitor 1A (P21)
CAGTTGTCAA 2 10 * NM_008300.2 Heat shock protein 4 (Hspa4)
CGGCAGAAGG 2 10 * NM_016666.1 AHR-interacting protein (Aip)
TCCGTCCCTC 2 10 * NM_145385.1 Myeloid leukemia factor 2 (Mlf2)
ACTGGGCCAT 2 9 * NM_025624.1 RIKEN cDNA
CCTTTGGGGT 2 9 * NM_010286.2 Tsc22d3
CTGACAGTCT 1 16 **** XM_620813.1 Pol-like transcript
AGTGTACCGT 1 10 ** NM_026958.1 RIKEN cDNA
CTGACAATGA 1 10 ** NM_007759.1 Retinoic acid-binding protein II (Crabp2)
GTTTCCCTTG 1 10 ** NM_011793.2 Barrier to autointegration factor 1 (Banf1)
CAGGTCCGTG 1 9 * NM_011065.2 Period homolog 1 (Per1)
CTGGAGTGAC 1 9 * NM_177809.2 Hypothetical protein
TGTAATTTCT 1 9 * NM_019771.1 Destrin (Dstn)
AGTGTGATAG 1 8 * NM_025926.1 DnaJ (Hsp40) homolog (Dnajb4)
CAAAGTTTAT 1 8 * XM_488509.2 Centrosomal protein 1 (Cep1)
CCACCGCAGC 1 8 * NM_139059.1 Casein kinase 1, transcript variant 2
TATCCTAGCC 1 8 * NM_029425.1 Suppressor of initiator codon mutations
CAAACTTAAC 1 7 * NM_013625.1 Platelet-activating factor acetylhydrolase
TGGTTGTACT 0 9 *** NM_009127.2 Stearoyl-coenzyme A desaturase 1 (Scd1)
CCATCCCCTT 0 8 *** NM_175307.2 RIKEN cDNA
GGAGTGAAAC 0 8 *** NM_175096.2 DNA segment, Chr 5
TTGAACTTTC 0 8 *** XM_619223.1 Friend virus susceptibility 1 (Fv1)
CTCACTGAGA 0 7 ** XM_356760.3 Similar to 60S ribosomal protein L17
CACCTGCTTC 0 6 * NM_172701.1 δ-like 3 (Dll3), transcript variant 1
TCTTCAGCAC 0 6 * NM_145558.1 Hydroxyacyl dehydrogenase (Hadhb)
AAGGGGGAAA 0 5 * XM_619685.1 cDNA sequence
ATCATGCTTC 0 5 * NM_009254.2 Serine proteinase inhibitor (Serpinb6c)
CCCACCCCAT 0 5 * NM_021523.3 Huwe1
CTCAAGAGAA 0 5 * NM_139297.2 UDP-glucose pyrophosphorylase 2 (Ugp2)
CTGAAGAAAT 0 5 * NM_008053.1 Fragile X mental retardation gene 1 (Fxr1h)
CTGCACCCGA 0 5 * NM_026366.1 RIKEN cDNA
CTGTGGATGA 0 5 * NM_016778.1 Bcl-2-related ovarian killer protein (Bok)
CTTGGTAACT 0 5 * NM_206924.1 Jumping translocation breakpoint (Jtb)
Repressed tags
TGACGTGCCG 118 53 **** XM_619956.1 Glyceraldehyde-3-phosphate dehydrogenase
GGCTCAACAA 89 33 **** NM_026020.2 Ribosomal protein, large P2 (Rplp2)
TGACCTGGCT 66 31 **** NM_025628.1 Cytochrome c oxidase, Cox6b1
TGCGCTTCCA 50 18 **** XR_000348.1 H3 histone, family 3A (H3f3a)
CAGCTCAGCC 48 21 *** NM_201353.1 Sema domain sequence (Sema5b)
AGCTGAAGGT 42 21 * XM_357202.3 RIKEN cDNA
ACCGACCGCA 38 14 **** NM_008410.1 Integral membrane protein 2B (Itm2b)
ACTCCTTTTG 36 17 ** NM_008617.2 Malate dehydrogenase 2 (Mdh2)
CGCGAATGCT 33 14 ** NM_010885.2 NADH dehydrogenase (Ndufa2)
GCCCTCATGC 31 15 * NM_023312.2 NADH dehydrogenase (Ndufa13)
AGGCCTTTAG 29 8 **** NM_011179.2 Prosaposin (Psap)
(continued on next page)
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Table 1 (continued)
SAGE tag Ctrl Aldo p Accession No. Gene
Repressed tags
CGGCGCCACA 28 8 *** NM_026305.1 Transcription elongation factor B (SIII)
TGACACCCAA 26 11 * XM_128725.5 NADH dehydrogenase (Ndufv2)
TTGCAAGGGG 24 9 ** NM_019770.2 RIKEN cDNA
TGACTCTGCC 21 6 *** NM_011652.2 Titin (Ttn)
CACGACGGAC 21 8 * XM_488885.2 Hypothetical LOC433272
AGCAAATATT 20 6 ** NM_026610.1 NADH dehydrogenase (Ndufb4)
TGACCCCATG 20 7 ** NM_025939.2 Phosphoribosylaminoimidazole carboxylase
GCCAAGCGGA 18 7 ** NM_023202.2 NADH dehydrogenase (Ndufa7)
AGGAGCTGGA 17 5 ** NM_181730.2 RNA polymerase 1-3 (Rpo1-3)
AGGCAGAATA 16 4 ** NM_030229.2 Polymerase (RNA) III (DNA polypeptide H)
TTGCCAGCCA 15 2 *** NM_025982.1 Sarcoma amplified sequence (Sas)
AAAAGTTGAA 15 3 ** NM_016672.1 Dopa decarboxylase (Ddc)
AGGCCTGAAC 15 4 * XM_485994.1 Protein phosphatase 1, catalytic subunit
TGCATCGTGA 14 2 *** NM_011185.1 Proteasome subunit, β type 1 (Psmb1)
ACCCTCAGGT 14 4 * NM_030225.3 Dihydrolipoamide S-succinyltransferase
TGAACACCCA 14 4 * NM_153526.2 Insulin-induced gene 1 (Insig1)
CAAATCAGGA 13 3 * XM_485597.2 Mus musculus similar to DnaJ-like protein 2
CACCGAAGGA 13 3 * XM_488877.1 LIM domain only 4 (Lmo4)
GTGGCTCCCA 13 3 * NM_025396.1 6-Phosphogluconolactonase (Pgls)
ATCAGTTAGA 12 3 * NM_144521.1 RIKEN cDNA
ATCAGTTAGA 12 3 * NM_011526.2 RIKEN cDNA
ACGGTTTTCT 11 1 ** NM_019760.1 Tumor differentially expressed 2 (Tde2)
ACCAAAGGTA 11 2 * NM_021552.2 Similar to TGF-β-inducible nuclear protein
CCTCACATCC 10 1 * NM_026027.1 Prefoldin 1 (Pfdn1)
CCCCCTTCCC 10 2 * NM_011670.1 Ubiquitin carboxy-terminal hydrolase L1
CCCTTTCTCT 10 2 * NM_026914.1 RIKEN cDNA
GCATTGCGCA 10 2 * NM_008948.1 Proteasome 26S subunit, ATPase 3 (Psmc3)
GTGGGCTTCA 10 2 * NM_021607.2 Nicastrin (Ncstn)
CAGTTTGCCT 9 1 * NM_029787.2 Diaphorase 1 (NADH) (Dia1)
ACCCCCTTCC 8 1 * NM_019581.2 GTP binding protein 2 (Gtpbp2)
TCAATTTTTT 8 1 * NM_011454.1 Serine proteinase inhibitor (Serpinb6b)
TGGCCAACGG 8 1 * NM_180678.2 Glycyl-tRNA synthetase (Gars)
TGACGCCGAG 7 0 * NM_008927.1 Mitogen-activated protein kinase kinase 1
TGAGTTTTAT 7 0 * XM_130033.7 Rho GTPase-activating protein 21
TGTCTTACCC 7 0 * NM_012010.2 Eukaryotic translation initiation factor 2
AAGTGGTCAA 6 0 * NM_173751.3 IlvB (bacterial acetolactate synthase)-like
CCAGAGCCAG 6 0 * XM_203523.3 cDNA sequence
CGCTGTACTC 6 0 * NM_013917.1 Pituitary tumor-transforming 1 (Pttg1)
CTCATGGATG 6 0 * NM_009722.1 Ca2+ transporting ATPase (Atp2a2)
GCGCGGACGC 6 0 * NM_026938.1 RIKEN cDNA
TGACATAGTG 6 0 * NM_027959.1 Protein disulfide isomerase (Pdia6)
*p<0.05, **p<0.01, ***p<0.005, ****p<0.001.
372 O. Muller et al. / Genomics 89 (2007) 370–377cardiomyocytes [7]. Aldosterone, the natural mineralocorticoid,
was shown to modulate the activity of Cl−/HCO3
− and Na+/H+
transporters and of L-type Ca2+ channels in neonatal and adult
rat cardiomyocytes, respectively [8,9].
Aldosterone and cortisol/corticosterone bind both the MR and
the glucocorticoid receptor (GR). Both hormones display higher
affinities for the MR than for the GR, whereas their respective
affinities for a given receptor are very similar [10]. In “classical”
aldosterone target cells (i.e., kidney and colon), the MR is
protected from illicit occupation by glucocorticoids thanks to
11β-hydroxysteroid dehydrogenase type II (11βHSD2), an
enzyme that converts cortisol/corticosterone into inactive meta-
bolites. Cardiomyocytes belong to the so-called “nonclassical”
aldosterone target tissues that express both the MR and the GR,
but not 11βHSD2. Thus, in cardiomyocytes, MR is not protected
from occupancy by glucocorticoids and is not aldosterone
selective. Taking into account that circulating cortisol/corticoster-one levels are at least 100-fold higher than those of aldosterone,
and that MR has the same affinity for aldosterone and
glucocorticoids, cardiomyocyte MR may be permanently occu-
pied by glucocorticoids. Thus, in cardiomyocytes, glucocorticoid
effects could be mediated by both GR andMR. This fact makes it
difficult to attribute the observed functional effects to glucocorti-
coids or aldosterone, on the one hand, and to GR or MR
activation, on the other hand.
To identify downstream target genes of different signaling
pathways potentially involved in cardiac remodeling and
hypertrophy, a serial analysis of gene expression (SAGE) was
performed, using RNA from primary culture of neonatal
C57BL/6 mouse cardiac myocytes stimulated for 4 h by LIF,
neuregulin-1, aldosterone, and angiotensin II. We have
previously described the results obtained from LIF stimulation
with the identification of the small proline-rich protein 1A as a
stress-inducible cardioprotective protein [11]. In the present
Fig. 2. Real-time quantitative RT-PCR analysis of Per1 mRNA expression. Total
RNAs were isolated from either untreated (control) or 10−6 M aldosterone-
treated cardiomyocytes after the indicated periods of time. Quantification of
Per1 mRNA expression was performed using real-time quantitative RT-PCR
analysis. Per1 expression levels were normalized to those of actin. Each value is
the mean±SEM. The experiment was performed in triplicate.
373O. Muller et al. / Genomics 89 (2007) 370–377report, we analyzed the effect of aldosterone on the same
cellular model, performed during the same experimental day.
Here, we identified a new set of 101 corticosteroid-regulated
genes. One candidate gene, ecto-ADP-ribosyltransferase-3
(Art3), was selected for further characterization. To discriminate
between glucocorticoid/mineralocorticoid and GR/MR effects
in cardiomyocytes, we analyzed the changes in Art3 protein
expression levels in response to the natural ligands (aldosterone
or corticosterone) in cardiomyocytes from wild-type, MR(null/
null), or GR(null/null) animals, allowing unequivocal attribu-
tion of the observed effect to the GR signaling pathway.
Results
Aldosterone-dependent transcriptome of neonatal mouse
cardiomyocytes
To characterize several major signaling pathways leading to
cardiomyocyte remodeling, we constructed five SAGE libraries
from neonatal mouse cardiomyocytes stimulated for 4 h with
aldosterone, LIF, neuregulin-1, angiotensin II, or control
medium (untreated) [11]. In the present study, we performed
the characterization and initial analysis of a SAGE library
constructed from aldosterone (10−6 M)-stimulated cells (Aldo
SAGE library). Importantly, at an aldosterone concentration of
10−6 M, both MR and GR are occupied by the hormone. Thus,
analysis of the Aldo SAGE library allowed us to characterize
both MR- and GR-regulated genes. The assessment of
significant differences among control and Aldo SAGE librariesFig. 1. Validation of SAGE candidates by Northern blot hybridization.
mRNAs were isolated from primary cultures of neonatal mouse cardiomyo-
cytes either untreated (C) or treated for 4 h with 10−6 M aldosterone (A). Two
independent experiments are presented for each condition. Blots were probed
with 32P-labeled Art3, Tsc22d3, or Pol-like transcript probes. The blot was also
probed with 32P-labeled α-myosin heavy chain (αMHC), to check for the equal
loading of cardiomyocyte-originated RNAs. These experiments were performed
at least four times for each of these transcripts and the results were always
similar.was performed by using Fisher's exact test (p<0.05). Such
analysis allowed the identification of 101 transcripts differen-
tially expressed between Aldo and control SAGE libraries (see
Table 1). To validate the SAGE data, Northern blot hybridization
was performed on three induced genes, namely, Art3, the Pol-
like transcript, and the glucocorticoid-induced leucine zipper
(Tsc22d3) (Fig. 1). One gene, namely period homolog 1 (Per1),
was validated using real-time quantitative RT-PCR analysis. As
shown in Fig. 2, Per1 mRNA levels were significantly increasedFig. 3. (A) Characterization of anti-ART3 antibody. The new antibody
recognizes two bands of ∼47 and ∼37 kDa (lane 1). To test for the specificity
of the antibody, the blot was probed either with the preimmune serum (lane 2) or
with immune serum incubated in the presence of GST protein (lane 3) or Art3 –
GST fusion protein (lane 4). (B) Time course of ART3 protein induction by
aldosterone. Primary cultures of neonatal mouse cardiomyocytes were stimulated
by aldosterone (10−6 M) for the indicated times. Proteins were recovered directly
in the SDS –PAGE sample buffer and run through 10% SDS –PAGE. This
experiment was performed three times.
374 O. Muller et al. / Genomics 89 (2007) 370–377at 4 h of aldosterone stimulation and remained equally
upregulated at 8 h of hormonal action.
Regulation of Art3 protein expression by 10−6 M aldosterone
Next, we addressed the question of aldosterone vs gluco-
corticoids andMR vs GR selectivity of transcriptional activation
of our identified transcripts. As an example, we performed this
analysis for Art3, an enzyme responsible for mono-ADP-
ribosylation of its target proteins [12]. We first developed an
anti-Art3 polyclonal antibody raised against the C-terminal part
of the Art3 protein. As shown in Fig. 3A, this antibody
specifically recognizes two bands with apparent molecular
masses (Mr) of ∼47 and ∼37 kDa that were absent when
probing was performed with the preimmune serum or when the
antibody was in competition with the Art3-GST fusion
protein. The time-course analysis revealed that aldosterone
stimulation of Art3 protein expression is delayed, compared to
Art3 mRNA expression, and reaches its maximal levels
between 24 and 32 h of aldosterone stimulation (Fig. 3B). The
32-h time point of stimulation with aldosterone/corticosterone
was chosen for all the following measurements of Art3 protein
expression.
Corticosterone- versus aldosterone-dependent activation of
Art3 expression
The 10−6 M concentration of aldosterone used in the
aforementioned experiments does not allow distinction between
aldosterone- and glucocorticoid-stimulatory effects, on the one
hand, or between MR- and GR-dependent effects, on the otherFig. 4. Determination of the EC50 values for stimulation of Art3 protein expressio
indicated doses of aldosterone or corticosterone for 32 h. Cardiomyocyte proteins wer
Bio-Rad Phosphoimager system.hand. Thus, in a first step toward the characterization of
hormonal and receptor specificity for Art3 expression regula-
tion, we determined the effective concentrations of aldosterone
and corticosterone for half-maximal response (EC50) in primary
culture of wild-type mouse cardiomyocytes. As shown in Fig. 4,
aldosterone and corticosterone stimulate Art3 protein expres-
sion with EC50 values of 39±9 (n=9) and 23±8 nM (n=7),
respectively. These experiments demonstrate that Art3 expres-
sion can be stimulated by physiologically relevant doses of
corticosterone but supraphysiological concentrations of aldos-
terone are required to produce the same effect. Therefore, these
experiments suggest that Art3 is a corticosterone-rather than an
aldosterone-regulated gene.
Art3 protein expression is stimulated exclusively via the GR
Since the previously mentioned experiments cannot exclude
the involvement of MR in corticosterone- (or aldosterone-)
mediated stimulation of Art3 expression, the requirement of MR
and/or GR in the activation of Art3 expression was tested in
mouse models selectively deprived of either MR or GR.
Because mice lacking the GR die within a few hours after birth
and mice lacking the MR die in the second week after birth
[13,14], the experiments were performed on mouse fetuses
delivered by cesarean section on day 18.5 of gestation. Two
minicultures of cardiomyocytes (2 wells of a 48-well plate)
were prepared from one heart of each genotype: one miniculture
served as a control and the other was stimulated with saturating
aldosterone concentration (10−6 M). In a set of control
experiments, the lack of MR expression and the presence of
GR in MR(null/null) mice, and the lack of GR expression andn by aldosterone and corticosterone. Cardiomyocytes were stimulated with the
e recovered and run in 10% SDS–PAGE.Western blots were quantified using the
Fig. 5. MR and GR expression in MR(null/null) and GR(null/null) mice.
Ethidium bromide-stained gels containing RT-PCR amplification products of
(A) GR or (B) MR mRNAs are shown. 35 PCR cycles were performed for all
samples. A single band of the expected size was obtained for both GR and MR
(408 and 335 bp, respectively).
Fig. 6. MR vs GR specificity of aldosterone effect on Art3 protein expression.
(A) Two minicultures of cardiomyocytes were prepared from one heart of
littermate mouse pups of each genotype: MR(+/+), MR(+/null), MR(null/null).
One miniculture served as a control (C) and the other was stimulated with
saturating aldosterone (A) concentration (10−6 M). (B) Two minicultures of
cardiomyocytes were prepared from one heart of littermate mouse pups of each
genotype: GR(+/+), GR(+/null), GR(null/null). One miniculture served as a
control (C) and the other was stimulated with saturating aldosterone (A)
concentration (10−6 M). These experiments were repeated four times with
identical results.
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RT-PCR analysis of corresponding mRNAs (Fig. 5). As shown
in Fig. 6A, the activation of Art3 expression by aldosterone was
fully maintained in MR(+/null) and MR(null/null) mice. In
contrast, knockout mutation of GR in GR(null/null) mice
resulted in a complete suppression of aldosterone activation of
Art3 expression (Fig. 6B). These experiments suggest that
corticosteroids regulate Art3 expression exclusively via the GR.
Discussion
Corticosteroid-regulated genes in cardiomyocytes
In this study, we identified a new set of 101 corticosteroid-
regulated transcripts in neonatal mouse cardiomyocytes.
Analysis of regulated transcripts revealed that only a small
fraction of these were previously identified as aldosterone- or
corticosterone/cortisol-regulated genes. Expression of Art3
[15], Tsc22d3 [16,17], Per1 [18], potassium channel Kcnj14
[19], ribosomal protein L7 [20], stearoyl-coenzyme A desatur-
ase 1 [21], cyclin-dependent kinase inhibitor p21 [22], and
diaphorase [23] has been shown to vary upon corticosteroid
treatment in different tissues and in different experimental
settings. In two of these genes, namely Tsc22d3 and Per1, the
glucocorticoid-responsive elements (GRE) have been charac-
terized [24,25]. Among four genes validated in this study either
by Northern hybridization or by quantitative real-time RT-PCR,
Art3 was identified as a prednisolone-induced transcript in
dystrophic skeletal muscle in a mouse model of Duchenne
disease [15]. Per1 gene expression was demonstrated to be
strongly upregulated by dexamethasone in fibroblasts [18].
Tsc22d3 has been recently shown to be a corticosterone-
upregulated transcript in rat cardiomyocytes [16]. Interestingly,
the expression of Tsc22d3 was found to be significantly inducedby dexamethasone in thymocytes [26], but selectively upregu-
lated by aldosterone in the kidney distal nephron [17]. The latter
demonstrates that the same transcript can be specifically
regulated by either glucocorticoids or aldosterone, in distinct
target tissue.
Here, using a combined pharmacological and transgenic
approach, we characterized the Art3 gene as being regulated by
glucocorticoids through the activation of GR in cardiomyocytes.
Identification of MR- vs GR-mediated signaling pathways in
classical vs nonclassical aldosterone target cells
Serum corticosterone and aldosterone levels are regulated by
distinct physiological/pathophysiological stimuli, but follow, in
normal situations, synchronous circadian secretion curves [27].
Serum corticosterone concentration is at least 100-fold higher
than that of aldosterone and varies in concentration, ∼10–
50 nM in the unbound form. Glucocorticoids (corticosterone/
cortisol) and aldosterone exhibit a similar high affinity to MR
(Kd∼0.5–2 nM) and a lower affinity to GR (Kd ~15–60 nM). In
classical aldosterone target tissues (distal nephron, colon), the
selectivity of MR to aldosterone is provided by the activity of
11βHSD2, which converts corticosterone/cortisol into inactive
metabolites.
In cardiomyocytes expressing very low levels of 11β-HSD2
activity, the role of aldosterone in MR activation remains
ambiguous. Three hypotheses have been proposed to explain
the MR-mediated effects in cardiomyocytes. A first hypothesis
proposes an endogenous synthesis of aldosterone in cardiac
tissues (cardiomyocytes, cardiofibroblast, or vessels). Accord-
ing to this hypothesis, the local aldosterone production in the
heart would be high enough to get tissue aldosterone concen-
376 O. Muller et al. / Genomics 89 (2007) 370–377tration comparable to that of plasma glucocorticoids [28]. This
interesting “auto or paracrine” model of aldosterone action has
been recently questioned by a comprehensive study of Gomez-
Sanchez et al. [29]. A new generation of highly specific anti-
aldosterone and anti-corticosterone antibodies was used to
demonstrate that cardiac aldosterone levels reflect directly those
measured in the general circulation. A second hypothesis
proposes that cardiac MR becomes accessible for aldosterone
only in pathophysiological situations, when circulating aldos-
terone levels are higher than normal [30]. However, from the
pharmacological viewpoint, it remains difficult to understand
how even elevated aldosterone levels can compete for MR
binding with glucocorticoids that are present at a 100-fold
concentration excess. A third hypothesis proposed by Funder
[31], not yet supported by strong experimental evidence,
implies that the tonic effect of glucocorticoids on MR could
be modulated by changes in the intracellular redox state upon
certain pathophysiological circumstances. In cardiomyocytes,
methodological factors make the analysis of MR vs GR
specificity much more difficult than in the kidney. There are
no established cardiomyocyte cell lines that would allow a
detailed analysis of MR and GR occupancy, as is possible in
mCCD cells [32]. Indeed, the very small amount of material that
can be obtained from primary cultures prevents such an
approach. Our method allows us to demonstrate as proof of
principle the transcriptional regulation of a specific gene
mediated by glucocorticoid activation of GR in cardiomyocytes.
The existence of MR-mediated and aldosterone-mediated
transcriptional effects in cardiomyocytes will require further
characterization of transcriptional regulation of identified
candidates by individual analysis of hormone and receptor
selectivity.
Materials and methods
Primary culture of neonatal mouse cardiomyocytes
Hearts from newborn mice or from mouse fetuses (day 18.5 of gestation)
were excised under sterile conditions and cut into four equal parts. After
extensive washing, these parts were transferred into an Eppendorf tube
containing 1 ml of Hanks’ medium (Gibco/Invitrogen), supplemented with
0.5 mg/ml trypsin (USB). Incubation with trypsin lasted overnight with gentle
agitation (700 rpm, Eppendorf Compact Thermomixer) at 4°C. At the end of
the incubation with trypsin, tissue was allowed to settle for 1 min, and the
500 μl trypsinization solution was removed and replaced by 500 μl of Light
medium composed of DMEM/M-199 media (3/1, v/v), supplemented with
1/100 times diluted (v/v) standard mix of penicillin/streptomycin/glutamine
(Gibco/Invitrogen) and 10 mM Hepes (pH 7.3). Tubes were incubated for
2.5 min with gentle agitation (1100 rpm, Eppendorf Compact Thermomixer) at
37°C. Tissue was allowed to settle and medium was replaced by 250 μl of
Hanks’ medium, supplemented with 300 U/ml collagenase type 2 (Worthing-
ton Biochemical). Tubes were incubated for 1.5 min with gentle agitation
(1100 rpm, Eppendorf Compact Thermomixer) at 37°C. Medium was
discarded and replaced by a new 250-μl aliquot of Hanks’/collagenase
solution. Tubes were incubated for 7 min at 37°C (1100 rpm, Eppendorf
Compact Thermomixer). Medium was removed and mixed with 250 μl of
Complete medium composed of the Light medium supplemented with 10%
horse serum and 5% fetal calf serum (Gibco/Invitrogen). The collagenase
digestion step was performed two additional times. The three fractions of
cardiac cells were centrifuged separately at 750 g for 5 min at 4°C. Medium
was discarded and cell pellets were pooled in 750 μl of Complete medium.Cells were plated in a single well of a 24-well plate and incubated for 1 h
15 min at 37°C (10% CO2). This step allows attachment of fibroblasts to the
well surface and their separation from other cells. This step was repeated once.
The remaining cells were plated in 2 wells of a 24-well plate coated with
gelatin and fibronectin. In the resulting culture, at least 85% of all cells were
cardiomyocytes. The cardiomyocytes were actively beating throughout the
experimental period (3 days). The MR(null/null) and GR(null/null) neonatal
mice were obtained by breeding of corresponding heterozygous mice bearing
one null and one wild-type allele [33,34].
Serial analysis of gene expression
SAGE libraries were prepared with 20 μg of poly(A) mRNA as described
[35]. A total of 250,350 tags were sequenced (63,445 tags for the control library,
60,446 for the aldosterone library, 62,676 for the LIF library, 61,611 for the
neuregulin library, and 62,618 for the AngII library). A total of 2927 different
tags, representing 2506 different genes, were found five or more times among
the five libraries. This number represents the actual number of genes assessed for
a significant up- or downregulation. Comparison between control and Aldo
SAGE libraries was performed by using Fisher's exact test. Two cut-off
thresholds were used to identify the differentially expressed SAGE tags: (i)
p<0.05 according to the Fisher test and (ii) a twofold change in tag numbers
between the two libraries.
Development of an anti-Art3 antibody and western blotting
Rabbit polyclonal antibody was developed against a C-terminal peptide
(D281MDN…NFEL370) of a mouse Art3 protein (NCBI Accession No.
CAA69284) fused to a GST construct. The antibody was affinity purified and
used at a 1:500 dilution. This antibody specifically recognizes a single band of
∼37 kDa and a nonspecific band of ∼43 kDa. Proteins were electrophoresed
through an 8–13% gradient SDS–PAGE and Western blotted, according to a
standard procedure. Western blots were quantified using the Bio-Rad
Phosphoimager scan system.
Quantitative real-time PCR analysis of Per1 gene expression
Primary cultures of neonatal mouse cardiomyocytes were either untreated
(control) or stimulated for 4 or 8 h with aldosterone (10− 6 M) Total RNA was
extracted and reverse transcribed using Superscript II reverse transcriptase
(Invitrogen). Real-time quantitative PCR analysis was performed using the
TaqMan system from Applied Biosystems. All reactions were performed in
triplicate. All primer sets used in this study were from Applied Biosystems:
TaqMan Gene Expression Assay PER1Mm00501813_m1 (for Per1) and mouse
ACTB (β-actin) Endogenous Control (for β-actin).
Qualitative RT-PCR analysis of GR and MR mRNA expression in
cardiomyocytes
Total RNA was extracted from cardiomyocytes originating from wild-type,
GR(null/null), or MR(null/null) mice. RT-PCR was performed using Titan One
Tube RT-PCR System (Roche). The sense and antisense primers designed to
amplify a 408-bp fragment of GR mRNA were 5′-CCTTGGAGGTCA-
GACCTGTT-3′ and 5′-CTTCTGATCCTGCTGCTGAG-3′, respectively. The
sense and antisense primers designed to amplify a 335-bp fragment of MR
mRNA were 5′-CCAGTTCTCCGTTCTCTGTA-3′ and 5′-CTTGAGCAC-
CAATCCGGTAG-3′, respectively. The amplification products were run on a
2.5% agarose gel and stained with ethidium bromide.Acknowledgments
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